11. |
- De Vin, Leo, 1957-, et al.
(author)
-
MMI: Engineering Studies with a Truly European Dimension
- 2006
-
In: Innovative teaching and learning in engineering education. ; , s. 99-106
-
Conference paper (peer-reviewed)abstract
- The paper describes a new engineering Master's program called MMII (manufacturing management and industrial informatics) that is co-located at universities in Sweden, Spain and the United Kingdom. One reason for developing the program was that the changing manufacturing landscape due to globalisation, increasing complexity of manufacturing systems itself and an increased need to integrate manufacturing systems with corporate information systems forces educators to find solutions that provide industry with engineers who have the right skills. Apart from "hard" skills related to the above-mentioned issues, industry increasingly also requires engineers to have well-developed "soft" skills such as an ability to work in an international environment and willingness to work abroad. A program given at only one location would not provide a truly European dimension and besides, it would draw heavily upon the teaching resources; hence the decision to seek international partners with complementing competences and resources; these were found at universities in Skövde, Valencia and Loughborough. In Loughborough, students read capita selecta from CAE (computer aided engineering) during one semester. In Valencia, they spend a project-based semester on international industrial management. In Skövde, they read virtual manufacturing during one semester and carry out their degree project during the final semester.
|
|
12. |
- El Kharraz, S., et al.
(author)
-
The androgen receptor depends on ligand-binding domain dimerization for transcriptional activation
- 2021
-
In: Embo Reports. - : EMBO. - 1469-221X .- 1469-3178. ; 22:12
-
Journal article (peer-reviewed)abstract
- Whereas dimerization of the DNA-binding domain of the androgen receptor (AR) plays an evident role in recognizing bipartite response elements, the contribution of the dimerization of the ligand-binding domain (LBD) to the correct functioning of the AR remains unclear. Here, we describe a mouse model with disrupted dimerization of the AR LBD (AR(Lmon/Y)). The disruptive effect of the mutation is demonstrated by the feminized phenotype, absence of male accessory sex glands, and strongly affected spermatogenesis, despite high circulating levels of testosterone. Testosterone replacement studies in orchidectomized mice demonstrate that androgen-regulated transcriptomes in AR(Lmon/Y) mice are completely lost. The mutated AR still translocates to the nucleus and binds chromatin, but does not bind to specific AR binding sites. In vitro studies reveal that the mutation in the LBD dimer interface also affects other AR functions such as DNA binding, ligand binding, and co-regulator binding. In conclusion, LBD dimerization is crucial for the development of AR-dependent tissues through its role in transcriptional regulation in vivo. Our findings identify AR LBD dimerization as a possible target for AR inhibition.
|
|
13. |
- Wilkinson, Tom M. A., et al.
(author)
-
Non-typeable Haemophilus influenzae protein vaccine in adults with COPD : A phase 2 clinical trial
- 2019
-
In: Vaccine. - : Elsevier BV. - 0264-410X .- 1873-2518. ; 37:41, s. 6102-6111
-
Journal article (peer-reviewed)abstract
- Loss of airway microbial diversity is associated with non-typeable Haemophilus influenzae (NTHi) infection and increased risk of exacerbation in chronic obstructive pulmonary disease (COPD). We assessed the safety and immunogenicity of an investigational vaccine containing NTHi antigens, recombinant protein D (PD) and combined protein E and Pilin A (PE-PilA), and AS01 adjuvant in adults with moderate/-severe COPD and prior exacerbations. In this phase 2, observer-blind, controlled trial (NCT02075541), 145 COPD patients aged 40-80 years randomly (1:1) received two doses of NTHi vaccine or placebo 60 days apart, on top of standard care. Reactogenicity in the 7-day post-vaccination period was higher following NTHi vaccine than placebo. Most solicited adverse events (AEs) were mild/moderate. At least one unsolicited AE was reported during the 30-day post-vaccination period by 54.8% of NTHi vaccine and 51.4% of placebo recipients. One serious AE (placebo group) was assessed by the investigator as vaccine-related. Anti-PD, anti-PE and anti-PiIA geometric mean antibody concentrations increased up to 30 days after each NTHi vaccine dose, waned thereafter, but remained higher than baseline (non-overlapping confidence intervals) up to 13 months post-dose 2. The frequency of specific CD4(+) T cells increased following two doses of NTHi vaccine and remained higher than baseline. Exploratory analysis showed a statistically non-significant lower yearly rate of moderate/severe exacerbations in the NTHi vaccine group than following placebo (1.49 versus 1.73) in the one-year period post-dose 2, with estimated vaccine efficacy of 13.3% (95% confidence interval -24.2 to 39.5; p = 0.44). The NTHi vaccine had an acceptable safety and reactogenicity profile and good immunogenicity in adults with COPD.
|
|